5ECKL KM, THOMSEN T, MOLLER M, et al. The bradycardic effect of the sinoatrial modulator S16257 [ J]. Eur Heart J, 1997, 18(SuaD1) abstract 1047.
6FOX K, FERRARI R, TENDERA M, et al. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabra- dine in patients with stable coronary artery disease and left ven- tricular systolic dysfunction:the morbidity-mortality evaluation of the If inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction (BEAUTIFUL) study[ J]. Am Heart J, 2006, 152(5) :860 -866.
7FOX K, FORD I, STEG PG,et al. Ivabradine for patients with sta- ble coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo controlled trial[ J]. Lancet,2008,372 (9641) :807 - 816.
8RAGUENEAU I, LAVEILLE C, JOCHEMSEN R, et al. Phar- macokinetic-pharmaeodynamie modeling of the effects of ivabra- dine, a direct sinus node inhibitor, on heart rate in healthy vol- unteers[J]. Clin Pharmacol Ther, 1998,64(2) : 192 -203.
9DUFFULL SB, AARONS L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for iv- abradine in healthy volunteers[ J] Eur J Pharm Sci, 2000, 10 (4) : 275 -284.
10DUFFULL SB, CHABAUD S, NONY P, et al. A pharmacoki- netic simulation model for ivabradine in healthy volunteers [ J ]. Eur J Pharm Sci, 2000, 10(4) : 285 -294.
